Federated Hermes’s Pacira BioSciences PCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-177
| Closed | -$2.66K | – | 2164 |
|
|
2024
Q3 | $2.66K | Sell |
177
-86,231
| -100% | -$1.47M | ﹤0.01% | 1923 |
|
|
2024
Q2 | $2.47M | Sell |
86,408
-9,045
| -9% | -$257K | 0.01% | 881 |
|
|
2024
Q1 | $2.79M | Sell |
95,453
-281,204
| -75% | -$8.64M | 0.01% | 851 |
|
|
2023
Q4 | $12.7M | Sell |
376,657
-11,810
| -3% | -$346K | 0.03% | 509 |
|
|
2023
Q3 | $11.9M | Sell |
388,467
-19,591
| -5% | -$706K | 0.03% | 493 |
|
|
2023
Q2 | $16.4M | Buy |
408,058
+258,394
| +173% | +$10.7M | 0.04% | 436 |
|
|
2023
Q1 | $6.11M | Buy |
149,664
+149,619
| +332,487% | +$5.95M | 0.02% | 653 |
|
|
2022
Q4 | $1.74K | Sell |
45
-149
| -77% | -$7.25K | ﹤0.01% | 2017 |
|
|
2022
Q3 | $10K | Sell |
194
-205
| -51% | -$11.4K | ﹤0.01% | 1837 |
|
|
2022
Q2 | $23K | Sell |
399
-80,543
| -100% | -$5.28M | ﹤0.01% | 1753 |
|
|
2022
Q1 | $6.18M | Sell |
80,942
-302
| -0.4% | -$20.1K | 0.01% | 728 |
|
|
2021
Q4 | $4.89M | Buy |
81,244
+19,112
| +31% | +$1.05M | 0.01% | 816 |
|
|
2021
Q3 | $3.48M | Sell |
62,132
-55,888
| -47% | -$3.22M | 0.01% | 908 |
|
|
2021
Q2 | $7.16M | Sell |
118,020
-19,998
| -14% | -$1.27M | 0.01% | 747 |
|
|
2021
Q1 | $9.67M | Sell |
138,018
-44,662
| -24% | -$3.19M | 0.02% | 667 |
|
|
2020
Q4 | $10.9M | Buy |
182,680
+4,275
| +2% | +$250K | 0.02% | 616 |
|
|
2020
Q3 | $10.7M | Buy |
178,405
+74,396
| +72% | +$4.32M | 0.03% | 556 |
|
|
2020
Q2 | $5.46M | Buy |
104,009
+85,673
| +467% | +$3.58M | 0.01% | 692 |
|
|
2020
Q1 | $615K | Buy |
18,336
+16,035
| +697% | +$666K | ﹤0.01% | 1315 |
|
|
2019
Q4 | $104K | Sell |
2,301
-115,249
| -98% | -$4.89M | ﹤0.01% | 1675 |
|
|
2019
Q3 | $4.47M | Sell |
117,550
-112,460
| -49% | -$4.49M | 0.01% | 798 |
|
|
2019
Q2 | $10M | Buy |
230,010
+22,173
| +11% | +$941K | 0.02% | 584 |
|
|
2019
Q1 | $7.91M | Sell |
207,837
-56,132
| -21% | -$2.19M | 0.02% | 647 |
|
|
2018
Q4 | $11.4M | Buy |
263,969
+79,415
| +43% | +$3.71M | 0.03% | 450 |
|
|
2018
Q3 | $9.07M | Buy |
+184,554
| New | +$7.98M | 0.02% | 604 |
|
|
2015
Q1 | – | Sell |
-15,094
| Closed | -$1.34M | – | 2056 |
|
|
2014
Q4 | $1.34M | Hold |
15,094
| – | – | ﹤0.01% | 1090 |
|
|
2014
Q3 | $1.46M | Buy |
15,094
+3,290
| +28% | +$320K | ﹤0.01% | 1075 |
|
|
2014
Q2 | $1.08M | Buy |
+11,804
| New | +$899K | ﹤0.01% | 1170 |
|
Other funds holding PCRX
DPCM
Federated Hermes's PCRX Position: Q4 2024 in Review
Federated Hermes sold out of Pacira BioSciences (PCRX) in Q4 2024, closing a stake of 177 shares — an estimated $2.66K sold.
Federated Hermes first reported a position in PCRX in Q2 2014 and held it in 28 quarters. The position peaked at $16.4M in Q2 2023. 233 funds tracked by Wall St. Rank hold PCRX as of Q4 2024.
- Federated Hermes reported no remaining Pacira BioSciences position as of Q4 2024 after selling out during the quarter.
- Federated Hermes sold 177 Pacira BioSciences shares in Q4 2024, an estimated $2.66K.
- Federated Hermes first reported a position in Pacira BioSciences in Q2 2014 and held it in 28 quarters.
- Federated Hermes's Pacira BioSciences position peaked at $16.4M in Q2 2023.
- 233 funds tracked by Wall St. Rank held Pacira BioSciences as of Q4 2024.
Based on Federated Hermes's 13F filing for Q4 2024, filed 13 Feb 2025.